Please assess the completion status of the following clinical trial:

Trial Title: Nigella Sativa in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mild COVID19 upper respiratory tract infection and with no evidence of pneumonia~* Adult (18 Years and above)~* Written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative).~* Understands and agrees to comply with planned study procedures.~* Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) available at KAUH.~Exclusion Criteria:~* Patients with pneumonia or severe illness requiring admission to ICU.~* Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) \< 30) or end stage renal disease requiring dialysis~* Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) \> 5 times the upper limit of normal).~* Pregnancy or breast feeding.~* Anticipated transfer to another hospital which is not a study site within 72 hours.~* Allergy to any study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NSO (Type: EXPERIMENTAL): Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
- Control (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).